Despite the association of FGFR3 alternations with a non-T cell-inflamed tumor microenvironment and the reduced sensitivity to immune checkpoint inhibitors (ICIs) [12, 13], recent studies have indicated that patients with BC respond equally to ICIs regardless of FGFR3 status [14, 15]. Here, FGFR3 is linked to breast cancer.